H. Lundbeck, Ebixa®, Lundbeck files for the mild to moderate indication for Alzheimer’s disease


                        
The European Medicines Agency (EMEA) has received Lundbeck’s filing for an extension of the indication for Ebixa® (memantine) to cover the treatment of mild to moderate Alzheimer’s disease. Ebixa® is currently approved for the treatment of moderately-severe to severe Alzheimer’s disease in Europe and in other markets around the world.

Subscribe

Documents & Links